PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--ColonaryConcepts LLC today announced the reacquisition of its proprietary colonoscopy preparation assets from Sebela Pharmaceuticals. ColonaryConcepts reacquired worldwide rights to the unique colon prep technology, EC Prep, which integrates active ingredients into nutritionally balanced bars and beverages, with a goal of improving patient experience. Terms of the transaction were not disclosed.
ColonaryConcepts originally sold its EC Prep™ technology to Sebela Pharmaceuticals in 2017. Sebela Pharmaceuticals and ColonaryConcepts agreed to the return of the rights to the EC Prep technology back to ColonaryConcepts.
“We are pleased to reengage in the clinical development of EC Prep,” said Herbert Stern, Chief Executive Officer of ColonaryConcepts. “We are excited to accelerate into Phase 3 clinical trials, targeting mid-2020. We are confident that they will reinforce the successful results from our Phase 2 trial, which showed successful colon cleansing, with over 90% of patients using the lead formulation having colonoscopies rated ‘excellent’ or ‘good’. Patients also reported a high rate of satisfaction, particularly compared with previous colonoscopy preps.”
Mr. Stern further commented, “EC Prep is a paradigm-shift in colon prep. We remain convinced that millions of patients will benefit from the advance in colonoscopy prep that ColonaryConcepts’ team has developed, and are delighted to propel this technology forward.”
ColonaryConcepts has been diligently pursuing the development of the balance of its patient-friendly technology platform, including novel approaches to treating various types of constipation. The company (through its subsidiary, ColonarySolutions) is currently planning a Phase 2 clinical trial for its lead product formulation (“C-Bar”™), which uses flavorful, chewable bars to treat patients with chronic idiopathic constipation (CIC).
About Colon Prep Market
There are more than 15 million colonoscopies performed in the United States annually. Continued market growth is expected due to the growth in the US population over the age of 45, increasing colon cancer awareness initiatives and the introduction of new technologies.
About ColonaryConcepts LLC
ColonaryConcepts LLC, headquartered in Palm Beach Gardens, FL, is committed to developing patient-centric innovations that improve gastrointestinal health. The company (through its subsidiary, ColonarySolutions) currently has one product candidate in clinical development: C-Bar™, a novel treatment for chronic constipation, which is currently on track for a Phase 2 trial, leveraging a successful Phase 1 clinical trial. ColonaryConcepts’ physician-led product development team includes Board-certified gastroenterologists, food scientists, pharmaceutical development experts, product design strategists, and culinary research chefs. For more information about ColonaryConcepts LLC, please visit http://www.colonaryconcepts.com.
